Aurinia Pharmaceuticals Inc.
AUPHNasdaqHealthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $62.5M | $50.3M | $175.5M | $21.6M | $914,000 | $50.1M |
| Operating income | $21.8M | −$13.3M | −$91.7M | −$37.9M | −$50.5M | −$104.3M |
| Net income | $23.3M | −$10.7M | −$78.0M | −$37.6M | −$50.4M | −$102.7M |
| Total assets | $751.6M | $550.6M | $548.1M | $470.9M | $543.4M | $463.7M |
| Total liabilities | $170.3M | $173.2M | $170.1M | $65.4M | $64.3M | $55.9M |
| Equity | $581.3M | $377.5M | $378.0M | $405.4M | $479.1M | $407.8M |
| EPS (diluted) | $0.16 | $-0.07 | $-0.54 | $-0.27 | $-0.40 | $-0.87 |
| Shares out. | 137.3M | 144.6M | 142.6M | 141.7M | 127.5M | 126.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 35.0%
- Net margin
- 37.4%
- Return on equity
- 4.0%
- Return on assets
- 3.1%
- Return on capital (ROCE)
- 3.3%
- Liabilities / assets
- 22.7%
- Debt / equity
- 0.29×
- Book value / share
- $4.23
- Revenue growth (YoY)
- 24.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 4.44safe
- Accruals / assets
- −14.9%clean
- Piotroski F-Score
- 8/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- LUPKYNISJan 22, 2021
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Recruitingreadout ~2029-03-02Study of Aritinercept in Patients With Generalized Myasthenia Gravis
- Phase 4Recruitingreadout ~2029-03-02PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.0M | 6.8 | +1.6% |
| Apr 30, 2026 | 8.9M | 8.7 | -2.5% |
| Apr 15, 2026 | 9.1M | 8.4 | -15.7% |
| Mar 31, 2026 | 10.8M | 8.8 | +6.4% |
| Mar 13, 2026 | 10.2M | 8.9 | +4.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or dispositionMay 11, 2026
- Results of operationsMay 7, 2026
- Entered a material agreement · Regulation FD disclosureApr 3, 2026
- Director / officer changeMar 23, 2026
- Results of operationsFeb 26, 2026
- Results of operationsNov 4, 2025
- Results of operations · Other material eventJul 31, 2025
- Other material eventJun 30, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.